P. J. McDowell

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.

I. Pavord, C. Brightling, R. Chaudhuri, 2021, The Lancet. Respiratory medicine.

Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX)

I. Pavord, C. Brightling, R. Chaudhuri, 2020 .

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

P. Merkel, J. Stone, P. Bekker, 2022, Seminars in Arthritis & Rheumatism.

Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index

J. Stone, L. Mcgarvey, L. Heaney, 2021, European Respiratory Journal.

The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.

P. Merkel, D. Murrell, P. Bekker, 2023, The Lancet. Rheumatology.